A New England Journal of Medicine report penned by scientists at Harvard Med and Google offers a blueprint for integrating machine learning into the practice of medicine as way to optimize clinical care.
Hospitals that perform the highest volume of transcatheter-aortic valve replacement (TAVR) procedures have significantly lower mortality rates than centers that do fewer of the minimally invasive surgeries.
Due to advances in treatment, an ever-increasing number of patients are living longer as metastatic cancer survivors. They and their doctors face a host of new challenges that require immediate attention.
The Valley Hospital participated in a landmark clinical trial that evaluated the ability of a novel, fully absorbable antibacterial envelope – the Medtronic TYRX™ Absorbable Antibacterial Envelope – to reduce infections associated with cardiac implantable electronic devices (CIEDs). The study found positive results and demonstrated that the envelope reduced the risk of major infection by 40 percent, and pocket infection by 61 percent, in patients at increased risk for infections receiving CIEDs, compared to standard-of-care pre-operative antibiotics.
Stanley Chetcuti, M.D., co-author on the Evolut trial of low-risk TAVR/ interventional cardiologist at Michigan Medicine (University of Michigan) comments on importance of both late-breaking clinical trials re: low-risk TAVR (Evolut and Partner 3) at the American College of Cardiology Scientific Sessions.
A new study by a team of cardiologists at Beth Israel Deaconess Medical Center (BIDMC) led by senior and corresponding author Jeffrey Popma, MD, suggests that a minimally invasive procedure currently reserved for patients too frail to undergo surgery may in fact be a safe and effective alternative for healthier patients.
A Cleveland Clinic-led research team has found that using an absorbable, antibiotic-eluting envelope when implanting cardiac devices like pacemakers and defibrillators can cut the rate of major infections by 40 percent. The research was presented today at the American College of Cardiology’s 68th Annual Scientific Session and simultaneously published in the New England Journal of Medicine. It will also be presented tomorrow at the European Heart Rhythm Association 2019 Congress.
S. Chris Malaisrie, MD, a cardiac surgeon at Northwestern Memorial Hospital, associate professor of surgery (cardiac surgery) at Northwestern University Feinberg School of Medicine and co-chair of the PARTNER 3 case review board, is available to comment on PARTNER 3.
Analysis shows the monthly rate of first-time opioid prescriptions dropped by more than half between 2012 and 2017. Though some physicians wrote no new prescriptions at all, others continued to prescribe dosages and durations that put patients at risk for misuse, overdose and death. Findings underscore importance of nuanced, individualized prescribing over all-or-nothing approach.
Two large national studies show that patient safety was unaffected and residents showed no signs of chronic sleep loss regardless of shift length.
The Clinical Research Forum recognized the Cedars-Sinai's Smidt Heart Institute with a 2019 Top Ten Clinical Research Achievement Award today for its study aimed at developing a blood pressure control program for African-American men in the comfortable and convenient environments of their barbershops. In just six short months, the study improved the outcomes and control of high blood pressure in more than 60 percent of participants.
A clinical trial at NewYork-Presbyterian/Columbia and other centers found that patients responded to a new “smart drug” for women with an aggressive form of breast cancer.
The first clinical study investigating the use of the direct oral anticoagulant, rivaroxaban, to prevent blood clots in patients with cancer at high-risk published today in the New England Journal of Medicine. The study found no significant reduction in venous thromboembolism or death in the overall 180-day trial period; however, the researchers did observe a lower incidence of these events while patients were actively on the study drug, or during the on-treatment period.
Thousands of Americans die each year during a dangerous two-minute procedure to insert a breathing tube. Now a Vanderbilt University Medical Center (VUMC) study in the New England Journal of Medicine (NEJM) is showing that using bag-mask ventilation, squeezing air from a bag into the mouth for 60 seconds to help patients’ breathing, improves outcomes and could potentially save lives.
A combination of two drugs – one of them an immunotherapy agent – could become a new standard, first-line treatment for patients with metastatic kidney cancer, says an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial.
Project CLEAR clinical trial finds that the application of antiseptic soap, mouthwash, and nose ointments prevent post-discharge MRSA infections and hospitalizations. Patients
Hospital patients who have methicillin-resistant Staphylococcus aureus (MRSA) can prevent future MRSA infections by following a standard bathing protocol after discharge, according to research results published in the February 14 issue of the New England Journal of Medicine.
Over a year and a half after the successful separation of two infant twins joined at the top of their heads, surgical team leaders report on this dramatic case. The surgeons describe the innovative devices, elaborate planning and precisely orchestrated teamwork needed to perform the complex separation surgery.
When patients fail to take prescribed medications—or don't use them the right way—they risk return trips to the hospital and cost the U.S. healthcare system more than $100 billion a year. Older hospital patients are most susceptible to drug-related problems that can lead to readmissions or even death. To help these individuals get the right medications and take them correctly after discharge, Cedars-Sinai has embedded pharmacists in the care teams treating certain high-risk patients. Medication lists are double-checked by a pharmacist for errors prior to discharge, and patients are sent home with their prescription drugs after being counseled on how to take them properly.
A landmark study has found that a newer targeted drug is significantly more effective than standard therapy for treating elderly patients with chronic lymphocytic leukemia (CLL). The drug, ibrutinib, attacks cancer cells without damaging normal cells, thus causing fewer side effects.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right